Aardvark Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4370 La Jolla Village Dr Ste 1050, San D...Phone Number
(858) 225-7696Website
www.aardvarktherapeutics.comRevenue
$7 MillionStock Symbol
AARDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Aardvark Therapeutics
Founded in 2017, Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. The company is headquartered in San Diego, California.Explore more
Aardvark Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aardvark Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Aardvark Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Aardvark Therapeutics is spiking on competitors!
Click to see if Aardvark Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Aardvark Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Aardvark Therapeutics has new funding data
Aardvark Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Aardvark Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Aardvark Therapeutics launches new products
Recommended Actions
Find VP level buyers at Aardvark Therapeutics
Find more new buyers
Compare Similar Companies to Aardvark Therapeutics
Compare insights from companies similar to Aardvark Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aardvark Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aardvark Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aardvark Therapeutics.
Aardvark Therapeutics financials insights
Gather financial insights about Aardvark Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15M
2021
Series B
$29M
2024
Series C
$85M
2025
Stock Offering
$94M
Aardvark Therapeutics Tech Stack
A closer look at the technologies used by Aardvark Therapeutics
Most Recent Scoops
Person-Based
Lawsuits, Legal Affairs
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Aardvark Therapeutics News & Media
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Aardvark to Contact Him Directly to Discuss Their Options NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds...Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately
Lead Plaintiff Deadline October 13, 2026 NEW YORK and SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a nationally recognized securities litigation law firm, announces that a securities class action lawsuit has been filed in the...AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
A securities class action alleges Aardvark Therapeutics promised investors a "99% gut-restricted" drug with "no serious adverse events" and Phase 3 data in early 2026; instead, cardiac observations paused the HERO trial and the FDA imposed a full clinical hold. NEW YORK, Sept. 2, 2026...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aardvark Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017, Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. The company is headquartered in San Diego, California.... Read More
